Click here to get full coverage on Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI  Stock Titan

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

Click here to get full coverage on JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9  Yahoo Finance

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance

Click here to get full coverage on Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?  simplywall.st

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st

Click here to get full coverage on Bearish Setup: How supply chain issues affect ALDX stock - Bull Run & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ

Bearish Setup: How supply chain issues affect ALDX stock - Bull Run & Real-Time Volume Analysis Alerts  BỘ NỘI VỤ

Bearish Setup: How supply chain issues affect ALDX stock - Bull Run & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ

Click here to get full coverage on H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10  富途牛牛

H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Click here to get full coverage on Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data  Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Click here to get full coverage on Insider Purchase: Principal Financial Officer of $ALDX Buys 2,500 Shares | ALDX Stock News - Quiver Quantitative

Insider Purchase: Principal Financial Officer of $ALDX Buys 2,500 Shares | ALDX Stock News  Quiver Quantitative

Insider Purchase: Principal Financial Officer of $ALDX Buys 2,500 Shares | ALDX Stock News - Quiver Quantitative

Click here to get full coverage on Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After  GlobeNewswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

Click here to get full coverage on Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE - StreetInsider

Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE  StreetInsider

Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE - StreetInsider

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?  Yahoo Finance

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $ALDX Given $9.0 Price Target - Quiver Quantitative

New Analyst Forecast: $ALDX Given $9.0 Price Target  Quiver Quantitative

New Analyst Forecast: $ALDX Given $9.0 Price Target - Quiver Quantitative

Click here to get full coverage on Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)  simplywall.st

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st

Click here to get full coverage on ALDX CLASS NOTICE: An Investigation has been Initiated on - GlobeNewswire

ALDX CLASS NOTICE: An Investigation has been Initiated on  GlobeNewswire

ALDX CLASS NOTICE: An Investigation has been Initiated on - GlobeNewswire

Click here to get full coverage on Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st

Don't Ignore The Insider Selling In Aldeyra Therapeutics  simplywall.st

Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st

Click here to get full coverage on Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade) - Seeking Alpha

Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade)  Seeking Alpha

Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade) - Seeking Alpha

Click here to get full coverage on Is ALDX stock a good choice for value investors - July 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ

Is ALDX stock a good choice for value investors - July 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts  BỘ NỘI VỤ

Is ALDX stock a good choice for value investors - July 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ

Click here to get full coverage on Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ)  Seeking Alpha

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results - GuruFocus

Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results  GuruFocus

Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results - GuruFocus

Click here to get full coverage on Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap - TradingView

Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap  TradingView

Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap - TradingView

Click here to get full coverage on Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity  Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Click here to get full coverage on Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N  GuruFocus

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Click here to get full coverage on After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX)  Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - simplywall.st

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?  simplywall.st

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - simplywall.st

Click here to get full coverage on 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals  Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga

Click here to get full coverage on Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter  Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Click here to get full coverage on After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off? - RTTNews

After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off?  RTTNews

After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off? - RTTNews

Click here to get full coverage on Jefferies raises Aldeyra Therapeutics stock price target to $7 on FDA acceptance - Investing.com

Jefferies raises Aldeyra Therapeutics stock price target to $7 on FDA acceptance  Investing.com

Jefferies raises Aldeyra Therapeutics stock price target to $7 on FDA acceptance - Investing.com

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading - The Globe and Mail

Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading  The Globe and Mail

Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading - The Globe and Mail

Click here to get full coverage on Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic  Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Click here to get full coverage on Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development - Stocktwits

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development  Stocktwits

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development - Stocktwits

Click here to get full coverage on Aldeyra Therapeutics Announces Positive Phase 2 Trial Results - TradingView

Aldeyra Therapeutics Announces Positive Phase 2 Trial Results  TradingView

Aldeyra Therapeutics Announces Positive Phase 2 Trial Results - TradingView

Click here to get full coverage on Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA  Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Click here to get full coverage on High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st

High Growth Tech Stocks In The US Market With Promising Potential  simplywall.st

High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st

Click here to get full coverage on Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics  Yahoo Finance

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Aldeyra Therapeutics Reports Positive Phase 2 Trial Results  TipRanks

Aldeyra Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Click here to get full coverage on FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

FDA Accepts Aldeyra’s Reproxalap Application for Review  TipRanks

FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

Click here to get full coverage on Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next?  timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Click here to get full coverage on Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

Aldeyra DED phase III hits but reproxalap field goal fumbled  BioWorld MedTech

Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

Click here to get full coverage on Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast - TipRanks

Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast  TipRanks

Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast - TipRanks

Click here to get full coverage on Aldeyra reshuffles pipeline, culling asset despite Phase II success - Yahoo Finance

Aldeyra reshuffles pipeline, culling asset despite Phase II success  Yahoo Finance

Aldeyra reshuffles pipeline, culling asset despite Phase II success - Yahoo Finance

Click here to get full coverage on June 2025's Spotlight On Promising Penny Stocks - Yahoo Finance

June 2025's Spotlight On Promising Penny Stocks  Yahoo Finance

June 2025's Spotlight On Promising Penny Stocks - Yahoo Finance

Click here to get full coverage on ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap  Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary  TradingView

Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Click here to get full coverage on Aldeyra Therapeutics announces positive results from phase 2 clinical trial in alcohol-associated hepatitis, focuses RASP product candidate pipeline on next-generation molecules - MarketScreener

Aldeyra Therapeutics announces positive results from phase 2 clinical trial in alcohol-associated hepatitis, focuses RASP product candidate pipeline on next-generation molecules  MarketScreener

Aldeyra Therapeutics announces positive results from phase 2 clinical trial in alcohol-associated hepatitis, focuses RASP product candidate pipeline on next-generation molecules - MarketScreener

Click here to get full coverage on Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal - Stock Titan

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal  Stock Titan

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal - Stock Titan

Click here to get full coverage on Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval - Ophthalmology Times

Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval  Ophthalmology Times

Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval - Ophthalmology Times

Click here to get full coverage on Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial - TipRanks

Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial  TipRanks

Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial - TipRanks

Click here to get full coverage on Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects (ALDX) - Seeking Alpha

Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects (ALDX)  Seeking Alpha

Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects (ALDX) - Seeking Alpha

Click here to get full coverage on Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX) - Seeking Alpha

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX)  Seeking Alpha

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX) - Seeking Alpha

Click here to get full coverage on ALDX - Aldeyra Therapeu Latest Stock News & Market Updates - Stock Titan

ALDX - Aldeyra Therapeu Latest Stock News & Market Updates  Stock Titan

ALDX - Aldeyra Therapeu Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on DEADLINE ALERT for RIDE/RIDEQ, BHC, SYNH, and ALDX: The Law - GlobeNewswire

DEADLINE ALERT for RIDE/RIDEQ, BHC, SYNH, and ALDX: The Law  GlobeNewswire

DEADLINE ALERT for RIDE/RIDEQ, BHC, SYNH, and ALDX: The Law - GlobeNewswire

Click here to get full coverage on Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission - Seeking Alpha

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission  Seeking Alpha

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission - Seeking Alpha

Click here to get full coverage on ALDX Stock Price and Chart — NASDAQ:ALDX - TradingView

ALDX Stock Price and Chart — NASDAQ:ALDX  TradingView

ALDX Stock Price and Chart — NASDAQ:ALDX - TradingView

Click here to get full coverage on Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights - Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights  Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights - Business Wire

Click here to get full coverage on Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer - Yahoo Finance

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer  Yahoo Finance

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics (ALDX) - Zacks Investment Research

Aldeyra Therapeutics (ALDX)  Zacks Investment Research

Aldeyra Therapeutics (ALDX) - Zacks Investment Research

Click here to get full coverage on Watchlist Movers: Canadian Solar Inc. (NASDAQ:CSIQ), Inovio Pharmaceuticals Inc (NASDAQ:INO), Aldeyra Therapeutics Inc (NASDAQ:ALDX) - Insider Financial

Watchlist Movers: Canadian Solar Inc. (NASDAQ:CSIQ), Inovio Pharmaceuticals Inc (NASDAQ:INO), Aldeyra Therapeutics Inc (NASDAQ:ALDX)  Insider Financial

Watchlist Movers: Canadian Solar Inc. (NASDAQ:CSIQ), Inovio Pharmaceuticals Inc (NASDAQ:INO), Aldeyra Therapeutics Inc (NASDAQ:ALDX) - Insider Financial

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis - MarketBeat

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis  MarketBeat

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Business Wire

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights  Business Wire

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Business Wire

Click here to get full coverage on Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights - Business Wire

Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights  Business Wire

Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights - Business Wire

Click here to get full coverage on Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial - PR Newswire

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial  PR Newswire

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial - PR Newswire

Click here to get full coverage on It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - Setenews

It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock  Setenews

It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - Setenews

Click here to get full coverage on Brokers Offer Predictions for ALDX Q1 Earnings - Defense World

Brokers Offer Predictions for ALDX Q1 Earnings  Defense World

Brokers Offer Predictions for ALDX Q1 Earnings - Defense World

Click here to get full coverage on HC Wainwright Has Bullish Estimate for ALDX FY2025 Earnings - Defense World

HC Wainwright Has Bullish Estimate for ALDX FY2025 Earnings  Defense World

ALDX

Price Chart

Key Statistics

Technicals

About ALDX

Latest News

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st

Advanced Charts

Top Gainers

Top Losers